Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse

Toxicology and Applied Pharmacology

Volumn 158, Issue 1, 1999, Pages 24-32

  Carthew, P ^a   Edwards, R E ^a   Nolan, B M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cell proliferation; Estradiol; Hypertrophy; Ovariectomized mouse; Raloxifene; Tamoxifen; Toremifene; Uterotrophic

Indexed keywords

BROXURIDINE; ESTRADIOL; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG EFFECT; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; HYPERTROPHY; MOUSE; NONHUMAN; UTERUS WEIGHT;

ANIMALIA;

EID: 0033168852     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8679     Document Type: Article

References (32)

1. Ashby J., Odum J., Foster J. R. Activity of raloxifene in immature and ovariectomised rat uterotrophic assays. Reg. Tox. Pharmacol. 25:1997;226-231.
2. Carmichael P. L., Ugwumadu A. H. N., Neven P., Hewer A. J., Poon G. K., Phillips D. H. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 56:1996;1475-1479.
3. Carthew P., Edwards R. E., Nolan B. M., Martin E. A., Smith L. L. Tamoxifen associated uterine pathology in rodents: Relevance to women. Carcinogenesis. 17:1996;101-106.
4. Carthew P., Edwards R. E., Nolan B. M., Tucker M. J., Smith L. L. Compartmentalised uterotrophic effects of tamoxifen, toremifene and estradiol in the ovariectomised Wister (Han) rat. Toxicol. Sci. 48:1999b;197-205.
5. Carthew P., Martin E. A., White I. N. H., Edwards R. E., Dorman B. M., Smith L. L. Tamoxifen induces short-term cumulative DNA damage and liver tumors, with and without promotion by phenobarbital. Cancer Res. 55:1995a;544-547.
6. 32P-postlabeling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumor formation. Carcinogenesis. 16:1995b;1299-1304.
7. Carthew P., Edwards R. E., Nolan B. M. Endometrial and vaginal cancer indicated in rats by tamoxifen, in the absence of endometrial hyperplasia. Am. Assoc. Cancer Res. 40:1999a;193.
8. Collins J. Estrogens and endometrial cancer - A reappraisal. J. Royal Soc. Med. 74:1981;403-406.
9. Dallenbach-Hellweg G., Hahn U., Schmidt D. Morphological changes observed in the endometrium during adjuvant therapy with tamoxifen. Zentralbl. Gynakol. 118:1996;365-369.
10. Di Salle E., Zaccheo T., Ornati G. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J. Steroid. Biochem. 36:1990;203-206.
11. Fisher B. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 90:1998;1371-1388.
12. Fornander T., Hellstom A. C., Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J. Natl. Cancer Inst. 85:1993;1850-1855.
13. Green J. A., Edwards R. E., Manson M. M. Immunohistochemical detection bromodeoxyuridine-labeled nuclei for in vivo cell kinetic studies. Manson M. M. Methods in Molecular Biology. 1992;131-135 The Humana Press, Totowa.
14. Hemminki K., Rajaniemi H., Lindahl B., Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56:1996;4374-4377.
15. Hulka B. Effect of exogenous estrogens on postmenopausal women: The epidemiological evidence. Obstet. Gynecol. Surv. 35:1980;389-399.
16. Jordan V. C., Rowsby L., Dix C. J., Prestwich G. Dose-related effects of non-steroidal antiestrogens and oestrogens on the measurement of cytoplasmic oestrogen receptors in the rat and mouse uterus. J. Endocrinol. 78:1978;71-81.
17. Kallio S., Kangas L., Blanco G., Johansson R., Karjalainen A., Perila M., Pippo I., Sundquist H., Sodervall M., Toivola R. A new triphenylethylene compound, Fc-1157a. Chemother. Pharmacol. 17:1986;103-108.
18. Kedar R. P., Bourne T. H., Powles T. J., Collins W. P., Ashley S. E., Cosgrove D. O., Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet. 343:1994;1318-1321.
19. Li D., Dragan Y., Jordan V. C., Wang M., Pitot H. C. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res. 57:1997;1438-1441.
20. Newbold R. R., Jefferson W. N., Padilla-Burgos E., Bullock B. C. Uterine carcinoma in mice treated neonatally with tamoxifen. Carcinogenesis. 18:1998;2293-2298.
21. O'Connor J. C., Cook J. C., Craven S. C., Van Pelt C. S., Obourn J. D. An in vivo battery for identifying endocrine modulators that are estrogenic or dopamine regulators. Fundam. Appl. Toxicol. 33:1996;182-195.
22. O'Regan R. M., Cisneros A., England G. M., MacGregor J. I., Muenzner H. D., Assikis V. J., Bilimoria M. M., Piette M., Dragan Y. P., Pitot H. C., Chatterton R., Jordan V. C. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Natl. Cancer Inst. 90:1998;1552-1558.
23. Paganinihill A., Ross R. K., Henderson B. E. Endometrial cancer and patterns of use of estrogen replacement therapy - A cohort study. Br. J. Cancer. 59:1989;445-447.
24. Pathak D. N., Pongracz K., Bodell W. J. Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite-e by uterine peroxidase to form DNA-adducts - Comparison with DNA-adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Carcinogenesis. 17:1996;1785-1790.
25. Powles T. J., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., Tidy A., Viggers J., Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 352:1998;98-101.
26. Reel J. R., Lamb J. C., Neal B. H. Survey and assessment of mammalian estrogen biological assays for hazard characterization. Fundam. Appl. Toxicol. 34:1996;288-305.
27. Riley D., Baum M., Macintyre J., Berstock D., Mckinna A., Jackson I., Sainsbury J. R. C., Wilson A., Wheeler T., Dobbs J., Rees G., Powles T., Rubens R., Haybittle J., Mcpherson K., Houghton J. The effect of adjuvant tamoxifen - The latest results from the Cancer Research Campaign Adjuvant Breast Trial. Eur. J. Cancer. 28A:1992;904-907.
28. Silva E. G., Tornos C. S., Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: The effect of tamoxifen. Int. J. Gynecol. Pathol. 13:1994;248-258.
29. Tucker M. J., Adam H. K., Patterson J. S. Tamoxifen. Laurence D. R., McLean A. E. M., Weatherall M. Safety Testing of New Drugs. 1984;125-161 Academic Press, London.
30. Van Leeuwen F. E., Benraadt J., Coebergh J. W. W., Kiemeney L. A. L. M., Gimbrere C. H. F., Otter R., Schouten L. J., Damhuis R. A. M., Bontenbal M., Diepenhorst F. W., Van den Belt-Dusebout A. W., Van Tinteren H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 343:1994;448-452.
31. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., Rotmensz N., Boyle P. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women. Lancet. 352:1998;93-97.
32. Williams G. M., Iatropoulos M. J., Djordjevic M. V., Kaltenberg O. P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 14:1993;315-317.